Novel T-Cell Based Immunotherapy Dosed Phase 2 Study of Patients With AML

March 03, 2021

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.

Expert Reviews Results of Carfilzomib Combination in R/R Multiple Myeloma

March 02, 2021

In an interview with Targeted Oncology, Hang Quach, MD, discussed the phase 2 Australasian Leukaemia and Lymphoma Group MM 018/ Asian Myeloma Network 002 study and how it can impact the treatment of R/R/ multiple myeloma in the future.

Pembrolizumab Indication for Treatment of Metastatic SCLC Withdrawn

March 02, 2021

Pembrolizumab has been withdrawn from the United States market as a treatment option for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Experts Compare Available Regimens for a Patient With Sarcomatoid Features

March 02, 2021

During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.

Quality of Life Maintained After Dose Doubling of Lanreotide Autogel in NETs

March 01, 2021

Treatment with lanreotide autogel in patients with pancreatic neuroendocrine tumors, and midgut neuroendocrine tumors did not cause deterioration in quality-of-life, according to new data from the Phase II CLARINET FORTE study.